← Leaderboards
David R Jones
University Of Virginia Charlottesville
$8,988,059
Attributed
$9,555,083
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,555,083 · 8
By mechanism
R01$7,586,888 · 4
T32$1,134,048 · 1
K08$664,625 · 1
M01$169,522 · 2
Top collaborators
- Craig Lee Slingluff5 shared
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationNeoplasm MetastasisGenetic TranscriptionMalignant Neoplasm Of LungSpecimenTranscriptional RegulationMediatingTumorMetastasis Suppressor GenesUnited StatesMetastasis SuppressionNuclearEpidermal Growth Factor ReceptorFutureOrganoidsTranscriptome SequencingMalignant NeoplasmsClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsGenesCellsLung AdenocarcinomaAdenocarcinoma CellBiobank
Grant awards (33)
Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma$544,255
R01 · FY2025 · CA · contact PI
Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma$583,127
R01 · FY2024 · CA · contact PI
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma$474,928
R01 · FY2023 · CA · contact PI
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma$474,928
R01 · FY2022 · CA · contact PI
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma$406,527
R01 · FY2022 · CA · contact PI
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma$559,847
R01 · FY2021 · CA · contact PI
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma$484,620
R01 · FY2021 · CA · contact PI
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma$559,847
R01 · FY2020 · CA · contact PI
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma$484,620
R01 · FY2020 · CA · contact PI
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma$543,053
R01 · FY2019 · CA · contact PI
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma$514,791
R01 · FY2019 · CA · contact PI
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma$414,944
R01 · FY2018 · CA · contact PI
Postdoctoral Training Grant for MDs in Surgical Oncology Research$236,759
T32 · FY2015 · CA
Postdoctoral Training Grant for MDs in Surgical Oncology Research$174,602
T32 · FY2014 · CA
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$233,989
R01 · FY2013 · CA · contact PI
Postdoctoral Training Grant for MDs in Surgical Oncology Research$223,367
T32 · FY2013 · CA
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$82,501
R01 · FY2013 · CA · contact PI
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$304,932
R01 · FY2012 · CA · contact PI
Postdoctoral Training Grant for MDs in Surgical Oncology Research$251,565
T32 · FY2012 · CA
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$304,932
R01 · FY2011 · CA · contact PI
Postdoctoral Training Grant for MDs in Surgical Oncology Research$247,755
T32 · FY2011 · CA
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$314,363
R01 · FY2010 · CA · contact PI
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1$300,684
R01 · FY2009 · CA · contact PI
INTRAPLEURAL DOCETAXEL IN MALIGNANT PLEURAL EFFUSION$8,018
M01 · FY2007 · RR · contact PI
INTRAPLEURAL DOCETAXEL IN MALIGNANT PLEURAL EFFUSION$66,631
M01 · FY2006 · RR · contact PI
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$66,622
K08 · FY2005 · CA
INTRAPLEURAL DOCETAXEL IN MALIGNANT PLEURAL EFFUSION$66,174
M01 · FY2005 · RR
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$133,245
K08 · FY2004 · CA
Intrapleural Docetaxel In Malignant Pleural Effusion$28,699
M01 · FY2004 · RR
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$133,245
K08 · FY2003 · CA
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$66,623
K08 · FY2002 · CA
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$133,245
K08 · FY2001 · CA
NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER$131,645
K08 · FY2000 · CA